Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Healthcare IT studies signal need for caution

This article was originally published in The Gray Sheet

Executive Summary

Patterns of IT use in healthcare need to be tailored to workers and their environment to be productive, according to an editorial by Robert Wears, MD, University of Florida, Jacksonville, and Marc Berg, MD, Erasmus University, Rotterdam, in the March 9 issue of JAMA. "Any IT acquisition or implementation trajectory should, first and foremost be an organizational change trajectory," they say. A JAMA study by Koppel et al. found that at one hospital a commonly used computerized, physician-order entry system "often facilitated medication error risks," despite being intended to help prevent errors. A separate review of 100 studies found that many such systems aid practitioner performance, but "effects on patient outcomes remain understudied and, when studied, inconsistent"...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel